Cullinan Therapeutics
$21.68
17
+$0.30+1.4% Friday 20:00
+$0.00+0%Friday 20:00After hours
Statistics
Day High
21.73
Day Low
21.67
52W High
22.54
52W Low
5.68
Volume
21,872
Avg. Volume
-
Mkt Cap
1.4B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.07
-0.96
-0.84
-0.73
Expected EPS
-0.84532
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-219.88MNet Income
Analyst Ratings
37.00Average Price Target
The highest estimate is 42.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CGEM. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap777.74M
Agios Pharmaceuticals
AGIO
Mkt Cap2B
Incyte
INCY
Mkt Cap24.36B
Exelixis
EXEL
Mkt Cap12.7B
Novartis
NVS
Mkt Cap286.78B
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
AMGEN
AMGN
Mkt Cap224.63B
About
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Show more...
CEO
Nadim Ahmed
Employees
109
Country
United States
ISIN
US2300311063
Listings
0 Comments
Share your thoughts
FAQ
What is Cullinan Therapeutics stock price today?▼
The current price of CGEM is $21.68 USD — it has increased by +1.4% in the past 24 hours. Watch Cullinan Therapeutics stock price performance more closely on the chart.
What is Cullinan Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cullinan Therapeutics stocks are traded under the ticker CGEM.
Is Cullinan Therapeutics stock price growing?▼
CGEM stock has risen by +6.59% compared to the previous week, the month change is a +22.83% rise, over the last year Cullinan Therapeutics has showed a +164.71% increase.
What is Cullinan Therapeutics market cap?▼
Today Cullinan Therapeutics has the market capitalization of 1.4B
When is the next Cullinan Therapeutics earnings date?▼
Cullinan Therapeutics is going to release the next earnings report on November 05, 2026.
What were Cullinan Therapeutics earnings last quarter?▼
CGEM earnings for the last quarter are -0.81 USD per share, whereas the estimation was -0.8 USD resulting in a -1.34% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cullinan Therapeutics revenue for the last year?▼
Cullinan Therapeutics revenue for the last year amounts to 0 USD.
What is Cullinan Therapeutics net income for the last year?▼
CGEM net income for the last year is -219.88M USD.
How many employees does Cullinan Therapeutics have?▼
As of August 22, 2026, the company has 109 employees.
In which sector is Cullinan Therapeutics located?▼
Cullinan Therapeutics operates in the Health & Wellness sector.
When did Cullinan Therapeutics complete a stock split?▼
The last stock split for Cullinan Therapeutics was on August 31, 2009 with a ratio of 2:1.
Where is Cullinan Therapeutics headquartered?▼
Cullinan Therapeutics is headquartered in CAMBRIDGE, United States.